Serina Therapeutics, Inc. (SER) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Serina Therapeutics, Inc. on January 9, 2026. The Company is a Delaware corporation with its principal executive offices in Huntsville, Alabama. The report addresses a regulatory notice received from The NYSE American LLC regarding compliance with continued listing standards.
Key Financial Metrics
The filing discloses specific equity figures but does not provide comprehensive revenue, profit, cash flow, or debt data.
- Stockholders' Equity: $1.6 million as of September 30, 2025.
- Profitability Status: The Company has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years ended December 31, 2024.
- Other Metrics: The filing text does not provide clear values for revenue, operating margins, cash flow, or total debt.
Material Changes and Listing Status
The Company received a notification from the NYSE American stating it is not in compliance with minimum stockholders' equity requirements. Specifically, the Company failed to meet the $4.0 million equity threshold required for entities reporting losses in three of the four most recent fiscal years.
- Compliance Deadline: The Company must submit a plan to regain compliance by February 8, 2026.
- Cure Period: If a plan is accepted, the Company has until July 9, 2027 (18 months from receipt of the letter) to regain compliance.
- Current Trading Status: The notice has no immediate impact on the listing; shares will continue to be listed and traded on the NYSE American pending compliance with other requirements.
Outlook, Risks, and Management Commentary
Management intends to submit a plan to regain compliance with NYSE American listing standards. However, the Company explicitly states there can be no assurance that it will achieve compliance within the Cure Period.
- Risk of Delisting: If the plan is not accepted by the NYSE American, delisting proceedings will commence. The Company retains the right to appeal a staff delisting determination.
- Operational Impact: The notice does not affect ongoing business operations or SEC reporting requirements.
Key Facts for Investor Verification
- Verify the Company's ability to raise capital or restructure to meet the $4.0 million equity requirement by July 9, 2027.
- Monitor the submission and acceptance status of the compliance plan by the February 8, 2026 deadline.
- Review the attached press release (Exhibit 99.1) for additional details on the Company's proposed remediation strategy.
- Assess the risk of potential delisting if the NYSE American rejects the proposed plan.